15 not yet recruiting, 13 recruiting, 10 unknown, 2 active not recruiting. 20 Phase 2, 16 Phase 1, 16 Phase 3.
Follow Shanghai JMT-Bio Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese Participants JMT206 injection, Semaglutide injection, Placebo injection - Valid MeSH Conditiongs | Phase 1 | Not yet recruiting | Shanghai JMT-Bio Inc. | 90 | 2026-10-20 | 2026-09-25 |
| A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer JSKN003, Trastuzumab, Pertuzumab - HER2-positive Recurrent or Metastatic Breast Cancer | Phase 2 | Not yet recruiting | Shanghai JMT-Bio Inc. | 60 | 2026-05-30 | 2026-04-22 |
| A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer KN026, HB1801, Trastuzumab - Resectable HER2-positive Breast Cancer | Phase 3 | Recruiting | Shanghai JMT-Bio Inc. | 1800 | 2026-03-06 | 2026-04-08 |
| SYS6090 Combination Therapy in Advanced Lung Cancer SYS6090 + pemetrexed + platinum-based chemotherapy, SYS6090 + paclitaxel + platinum-based chemotherapy, SYS6090 + docetaxel - Non-Small Cell Lung Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | Shanghai JMT-Bio Inc. | 596 | 2026-02-28 | 2026-03-16 |
| JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan JSKN003, Physician choiced treatment, include: TAS-102, Regorafenib, Fruquintinib. - HER2-positive Colorectal Cancer | Phase 3 | Not yet recruiting | Shanghai JMT-Bio Inc. | 123 | 2026-02-06 | 2026-02-03 |
| Evaluate the Safety, Tolerability, PK, and PD of JMT206 Injection in Healthy Participants JMT206, Placebo - Healthy Participants | Phase 1 | Recruiting | Shanghai JMT-Bio Inc. | 44 | 2026-01-26 | 2026-02-19 |
| A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer KN026, Capecitabine, Enlonstobart - HER2-positive Gastric Cancer | Phase 2 / Phase 3 | Not yet recruiting | Shanghai JMT-Bio Inc. | 490 | 2025-12-30 | 2026-01-12 |
| Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors JMT108 - Unresectable Locally Advanced or Metastatic Melanoma, Unresectable Locally Advanced or Metastatic Urinary Tract Tumors | Phase 1 / Phase 2 | Recruiting | Shanghai JMT-Bio Inc. | 500 | 2025-12-17 | 2026-08-18 |
| The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer JMT101, Irinotecan, Regorafenib - Metastatic Colorectal Cancer (mCRC) | Phase 3 | Not yet recruiting | Shanghai JMT-Bio Inc. | 252 | 2025-10-01 | 2025-08-21 |
| JMT106 Injection in the Treatment of Advanced Solid Tumors JMT106 Injection - Advanced Solid Tumor, Lung Squamous Cell Carcinoma | Phase 1 | Recruiting | Shanghai JMT-Bio Inc. | 200 | 2025-09-25 | 2025-12-18 |
| a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia JMT202 injection, Placebo - Hypertriglyceridemia | Phase 1 / Phase 2 | Recruiting | Shanghai JMT-Bio Inc. | 48 | 2025-09-09 | 2025-12-30 |
| A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy JMT601 Injection, Rituximab, Cyclosporin Capsules - Primary Membranous Nephropathy | Phase 2 | Not yet recruiting | Shanghai JMT-Bio Inc. | 156 | 2025-06-30 | 2025-06-19 |
| JSKN003 Combined Treatment of HER2-positive Gastric Cancer JSKN003, KN026, Capecitabine - HER2-positive Gastric Cancer | Phase 2 | Not yet recruiting | Shanghai JMT-Bio Inc. | 153 | 2025-06-15 | 2025-05-31 |
| First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors JMT108, Pembrolizumab, Ivonescimab - Advanced Malignant Tumors | Phase 1 / Phase 2 | Recruiting | Shanghai JMT-Bio Inc. | 436 | 2025-04-11 | 2026-01-29 |
| A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs Glumetinib, Osimertinib mesylate, Pemetrexed - Non-Small Cell Lung Cancer | Phase 3 | Recruiting | Shanghai JMT-Bio Inc. | 350 | 2025-04-03 | 2025-04-08 |
| Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients Glumetinib Tablets, Osimertinib Mesylate Tablets, Glumetinib Tablets Placebo - Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression | Phase 2 / Phase 3 | Not yet recruiting | Shanghai JMT-Bio Inc. | 390 | 2025-04-01 | 2025-04-03 |
| JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer Mitoxantrone Hydrochloride Liposome, JMT101 injection, Capecitabine - Recurrent or Metastatic Nasopharyngeal Cancer, Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy | Phase 2 | Not yet recruiting | Shanghai JMT-Bio Inc. | 150 | 2025-04-01 | 2025-03-25 |
| JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer JSKN003, Trastuzumab emtansine (T-DM1) - Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants | Phase 3 | Recruiting | Shanghai JMT-Bio Inc. | 228 | 2025-02-18 | 2025-03-24 |
| A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer KN026, HB1801, Pertuzumab - Early or Locally Advanced HER2-positive Breast Cancer | Phase 3 | Active not recruiting | Shanghai JMT-Bio Inc. | 520 | 2024-12-16 | 2026-07-07 |
| A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations JMT101, Osimertinib - Locally Advanced or Metastatic Non-squamous NSCLC, Harboring EGFR Sensitive Mutations NSCLC | Phase 3 | Recruiting | Shanghai JMT-Bio Inc. | 516 | 2024-10-23 | 2024-12-16 |
Showing 20 of 43. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (8) · Giant Cell Tumor of Bone (3) · Breast Neoplasms (2) · Colorectal Neoplasms (2) · Recurrence (2) · Bone Diseases (1) · Carcinoma, Hepatocellular (1) · Humoral Hypercalcemia Of Malignancy (1) · Hypertriglyceridemia (1) · Lymphoma, B-Cell (1) · Melanoma (1) · Multiple Myeloma (1) · Nasopharyngeal Neoplasms (1) · Osteoporosis, Postmenopausal (1) · Pancreatic Neoplasms (1)
Docetaxel (8) · osimertinib (8) · Trastuzumab (6) · Denosumab (4) · Irinotecan (4) · pertuzumab (4) · Capecitabine (3) · Carboplatin (3) · Cisplatin (3) · Pemetrexed (3) · regorafenib (3) · Fluorouracil (2) · Oxaliplatin (2) · Paclitaxel (2) · glumetinib (2)
China (28)
Li Zhang, M.D. (3) · Jin Li, MD (2) · Li Zhang (2) · Jian Hou, M.D. (1) · Jianping Li, doctor (1) · Jin LI, PHD (1) · Weibo Xia (1) · Weili Zhao (1) · Xiaohui Niu, B.M. (1) · Xiugao Yang (1) · Zhimin Shao, M.D. Organizational Affiliatio (1)
PMID 41292259, PMID 35992822, PMID 37308490, PMID 39500883, PMID 39853667, PMID 40686685, PMID 42690668